Recently a new oral drug is approved for treatment of multiple myeloma. It acts as a selective inhibitor of nuclear expo. Which drug is it ?
Multiple myeloma is a cancer of plasma cells. Common treatments include proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies. But the question specifies a nuclear export inhibitor. I remember that XPO1 (exportin 1) is a key protein involved in nuclear export. Inhibiting it would trap certain proteins, like tumor suppressors, in the nucleus, preventing their degradation. Selinexor is a drug that inhibits XPO1. It's an oral medication and was approved more recently. Let me check if that's correct. Yes, Selinexor (brand name Xpovio) was approved by the FDA in 2019 for relapsed/refractory multiple myeloma. It works by blocking the nuclear export protein XPO1, leading to the accumulation of tumor suppressor proteins in the nucleus, which induces apoptosis in cancer cells.
Now, the options A, B, C, D are not listed, but the correct answer is Selinexor. The incorrect options might be other drugs like lenalidomide (an immunomodulatory agent), bortezomib (a proteasome inhibitor), or daratumumab (a monoclonal antibody). Each of these has different mechanisms and would be incorrect here. The clinical pearl here is that Selinexor is the first oral XPO1 inhibitor approved for myeloma, and students should remember its mechanism and indication. The key is the nuclear export inhibition, which is a unique mechanism compared to other myeloma drugs. I need to structure the explanation with the core concept, correct answer explanation, why others are wrong, and a clinical tip.
**Core Concept**
Nuclear export inhibition in multiple myeloma targets XPO1 (exportin-1), a protein that transports cargo like tumor suppressors out of the nucleus. Inhibiting XPO1 traps these proteins in the nucleus, inducing apoptosis in myeloma cells. This mechanism is distinct from proteasome inhibition or immunomodulatory pathways.
**Why the Correct Answer is Right**
Selinexor (Xpovio) is a selective XPO1 inhibitor approved for relapsed/refractory multiple myeloma. By blocking nuclear export, it retains tumor suppressors (e.g., p53) and pro-apoptotic proteins in the nucleus, leading to cell death. Its oral bioavailability and unique mechanism make it a key therapy for patients with limited options.
**Why Each Wrong Option is Incorrect**
**Option A:** Bortezomib is a proteasome inhibitor, not a nuclear export inhibitor.
**Option B:** Lenalidomide is an immunomodulatory agent that enhances T-cell activity and inhibits angiogenesis.
**Option C:** Daratumumab is a monoclonal antibody targeting CD38 on myeloma cells.
**Option D:** Carfilzomib is another proteasome inhibitor, not acting on nuclear export pathways.
**Clinical Pearl / High-Yield Fact**
Selinexor is the first FDA-approved oral XPO1 inhibitor